Experiences with

Chlorambucil

[i][/i] [i]Patients were divided into 3 groups:[/i] [i] 1) acalabrutinib alone[/i] [i] 2) acalabrutinib plus obinutuzumab, a monoclonal antibody[/i] [i]3) the usual chemoimmunotherapy treatment (chlorambucil plus a monoclonal antibody).

Although if I had it my way, I want to be able to be treated with Chlorambucil another chemotherapy which has been known to induce long term remissions in people with severe refractory cases of posterior uveitis.

Prior to the advent of targeted therapies, we only had chemoimmunotherapy treatments, typically BR (bendamustine+rituximab) or a very old drug chlorambucil to offer to most patients needing treatment.

I was previously treated with Obinutuzumab and Chlorambucil for 5 sessions and this proved to be very effective as my bloods all returned to ‘normal’ very quickly and I have remained very well during and after the treatment.

[/i] [i]However, only trends toward improvement in overall survival have been seen as compared with chlorambucil and obinutuzumab. These approaches are based on the principle that “one size fits all,” and therapy is not individualized on the basis of response.

This consisted of 5 cycles of Obinutuzumab + chlorambucil which very successfully addressed my CLL and returned all my bloods to normal very quickly. During this 4 year period I haven't experienced any problems at all.

My doctor initially had me take a low dose of (50% normal) Chlorambucil for a few weeks to bring down the lymphocyte count into the low 100s. I have had my first two weeks of Obin (100/900 mg & 1000 mg) and had a question which I haven't been able to find answered online anywhere else.

of follow-up, PFS was significantly longer in patients treated with Acalabrutinib plus Obinutuzumab versus Acalabrutinib, while median OS was not reached in any treatment arm and was considerably longer in patients treated with Acalabrutinib-Obinutuzumab versus Obinutuzumab-Chlorambucil

I was treated for CLL in 2018 - chlorambucil and Gazyvaro. No problems at all until last month a random blood test indicated an over active thyroid, for which I am now taking medication. I understand that both conditions relate to the immune system.

I was diagnosed in 1998 and given a small amount of prednisone and chlorambucil and have received nothing since except ivig which started in June2021 due to infections.

Due to enlarged under arm lymph nodes and wbc of 35000 I was treated after diagnosis with what they gave at that time which was called pulse dosing of chlorambucil and prednisone for 4 days a month for 4 months.

When lymphocytes progressed had Retuxan and Chlorambucil 4 rounds in 2017. Count started going back up in 2021. I would be very pleased to get more knowledge of my “new” disease. Thankyou Jennifer_africa

In the randomized phase III CLL11 study, either obinutuzumab or rituximab was combined with chlorambucil compared with chlorambucil alone for patients with previously untreated CLL and coexisting conditions.

I knew Chlorambucil use for CLL dated back to the 1950's but I hadn't appreciated that was also the case for cyclophosphamide, (the 'C' in FCR).

Study participants were treated with six cycles of either venetoclax-obinutuzumab (VO) or chlorambucil-obinutuzumab (CO); the 4-year PFS was 74% vs. 35.4% (P < .0001) respectively.

I've enjoyed a remission of around 2 yrs following chlorambucil and obinutuzimab. I'd appreciate any comment or suggestions about joint pain as this has come as an unpleasant surprise.

She went through several treatments: Chlorambucil for 3 yrs, then Bendamustine/Rituximab (6 cycles) with remission for 1.5 yrs. Afterwards, her CLL transformed to B-PLL (pro-lymphocytic transformation) with 17p deletion so she was recommended to start on Ibrutinib (Imbruvica) from late 2019.

Until recently, chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab (FCR), bendamustine and rituximab, and chlorambucil and obinutuzumab were considered standard first-line therapy for patients with CLL.

plus obinutuzumab or chlorambucil plus obinutuzumab.

Fixed duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study.